We proposed treatment to patients with IGF-1 > 1.2 ULN, as these levels were demonstrated to correlate with poor outcomes in treated patients ( 34 ), with an increasing trend and comorbidities.
← all excerpts
Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study.
1
—
—